Autoimmune Hepatitis
60
15
18
20
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
5 terminated out of 60 trials
80.0%
-6.5% vs benchmark
10%
6 trials in Phase 3/4
25%
5 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (60)
Belimumab in Autoimmune Hepatitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
Machine Learning for Prediction of Therapy Response in Autoimmune Hepatitis
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
Liver Cirrhosis Network Cohort Study
Repeatability and Reproducibility of Multiparametric MRI
A Study of SIPLIZUMAB in AILD and LT Patients
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
TruGraf Liver Gene Expression Serial Test
Swiss Autoimmune Hepatitis Cohort Study
Host-Diet-Gut Interaction Post Vegan Diet in Pediatric Autoimmune Hepatitis.
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients
Role of USP35 in the Detection of Ferroptosis in Juvenile Autoimmune Hepatitis
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
Efficacy and Safety of Therapeutic Plasma Exchange vs Standard Medical Therapy in Severe Autoimmune Hepatitis.
Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis?
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease